Proton pump inhibitors may reduce tumour resistance

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 7, 2005, Pages 1049-1054

  De Milito, Angelo ^a   Fais, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Acidity; Chemotherapy; pH; Proton pump inhibitors; Resistance to drugs; Tumours

Indexed keywords

ABC TRANSPORTER; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; BICARBONATE; BREAST CANCER RESISTANCE PROTEIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ESOMEPRAZOLE; FLUOROURACIL; LANSOPRAZOLE; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP; PROTON PUMP INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; RABEPRAZOLE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACIDITY; CANCER CHEMOTHERAPY; CELL ACTIVITY; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL NUCLEUS; CELL ORGANELLE; CYTOPLASM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR SPACE; HOMEOSTASIS; HUMAN; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MICROENVIRONMENT; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; NONHUMAN; PEPTIC ULCER; PH; PH MEASUREMENT; SOLID TUMOR; STOMACH ACID SECRETION; STRUCTURE ANALYSIS; TUMOR CELL; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS, EXPERIMENTAL; ORGANELLES; P-GLYCOPROTEINS; PROTON PUMPS; VACUOLAR PROTON-TRANSLOCATING ATPASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 21844474548     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.7.1049     Document Type: Editorial

References (44)

1. GOTTESMAN MM, PASTAN I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. (1993) 62:385-427.
2. LUCIANI F, MOLINARI A, LOZUPONE F et al.: P-glycoprotein-actin association through ERM family proteins: a role in P-glycoprotein function in human cells of lymphoid origin. Blood (2002) 99:641-648.
3. IVETIC A, RIDLEY AJ: Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology (2004) 112:165-176.
4. RAGHUNAND N, HE X, VAN SLUIS R et al.: Enhancement of chemotherapy by manipulation of tumor pH. Br. J. Cancer (1999) 80:1005-1011.
5. TANNOCK IF, ROTIN D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. (1989) 49:4373-4384.
6. IZUMI H, TORIGOE T, ISHIGUCHU H et al.: Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev. (2003) 29:541-549.
7. MAHONEY BP, RAGHUNAND N, BAGGET B, GILLIES RJ: Tumor acidity, ion trapping and chemotherapeutics I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol. (2003) 66:1207-1218.
8. SIMON S, ROY D, SCHINDLER M: Intracellular pH and the control of multidrug resistance. Proc. Natl. Acad. Sci. USA (1994) 91:1128-1132.
9. NEWELL K, WOOD P, STRATFORD I, TANNOCK I: Effects of agents which inhibit the regulation of intracellular pH on murine solid tumors. Br. J. Cancer (1992) 66:311-317.
10. RAGHUNAND N, GILLIES RJ: pH and drug resistance in tumors. Drug Resist. Update (2000) 3:39-47.
11. OHTSUBO T, IGAWA H, SAITO T et al.: Acidic environment modifies heat- or radiation-induced apoptosis in human maxillary cancer cells. Int. J. Radiat. Oncol. Biol. Phys. (2001) 49:1391-1398.
12. RAGHUNAND N, MARTINEZ-ZAGUILAN R, WRIGHT SH, GILLIES RJ: pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem. Pharmacol. (1999) 57:1047-1058.
13. SCHINDLER M, GRABSKI S, HOFF E, SIMON SM: Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry (1996) 35:2811-2817.
14. HURWITZ SJ, TERASHIMA M, MIZUNUMA N, SLAPAK CA: Vesicular anthracycline accumulation in doxorubicin-selected U937 cells: participation of lysosomes. Blood (1997) 89:3745-3754.
15. ALTAN N, CHEN Y, SCHINDLER M, SANFORD SM: Defective acidification in human breast tumor cells and implications for chemotherapy. J. Exp. Med. (1998) 187:1583-1598.
16. LARSEN AK, ESCARGUEIL AE, SKLADANOWSKI A: Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. (2000) 85:217-229.
17. LUCIANI F, SPADA M, DE MILITO A et al.: Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst. (2004) 96:1702-1713.
18. RAGHUNAND N, MAHONEY BP, VAN SLUIS R, BAGGETT B, GILLIES RJ: Acute metabolic alkalosis enhances response of C3H muose mammary tumors to weak base mitoxantrone. Neoplasia (2001) 3:227-235.
19. RAGHUNAND N, MAHONEY BP, GILLIES RJ: Tumor acidity, ion trapping and chemotherapeutics II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic therapeutic agents. Biochem. Pharmacol. (2003) 66:1219-1229.
20. DIETEL M, ARPS H, LAGE H, NIENDORF A: Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res. (1990) 50:6100-6106.
21. BOBICHON H, COLIN M, DEPIERREUX C, LIAUTAUD-ROGER F, JARDILLIER JC: Ultrastructural changes related to multidrug resistance in CEM cells: role of cytoplasmic vesicles in drug exclusion. J. Exp. Ther. Oncol. (1996) 1:49-61.
22. CLEARY I, DOHERTY G, MORAN E, CLYNES M: The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. Pharmacol. (1997) 53:1493-1502.
23. BOUR-DILL C, GRAMAIN MP, MERLIN JL, MARCHAL S, GUILLEMIN F: Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis. Cytometry (2000) 39:16-25.
24. OUAR Z, LACAVE R, BENS M, VANDEWALLE A: Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug resistant cells. Cell Biol. Toxicol. (1999)15:91-100.
25. LUGINI L, LOZUPONE F, MATARRESE P et al.: Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab. Invest. (2003) 83:1555-1567.
26. ANDREOLA G, RIVOLTINI L, CASTELLI C et al.: Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. (2002) 195:1303-1316.
27. TAYLOR DD, TAYLOR CG: Tumor-derived exosomes and their role in cancer-associated T-cell signalling defects. Br. J. Cancer (2005) 1-7 (Epub ahead of print).
28. +)-ATPases - Nature's most versatile proton pumps. Nat. Rev. Mol. Cell Biol. (2002) 3:94-103.
29. +-ATPase types in the ruffled borders of osteoclasts. J. Cell Biol. (1990) 111:1305-1311.
30. MARQUARDT D, CENTER MS: Involvement of vacuolar H+-adenosine triphosphatase activity in multidrug resistance in HL60 cells. J. Natl. Cancer Inst. (1991) 83:1098-1102.
31. +ATPases are functionally expressed in the plasma membranes of human tumor cells. Am. J. Physiol. (1993) 265:C1015-C1029.
32. MURAKAMI T, SHIBUYA I, ISE T et al.: Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int. J. Cancer (2001) 93:869-874.
33. +-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J. (2003) 370:185-193.
34. LARSSON H, MATTSON H, SUNDELL G, CARLSSON E: Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo. Scand. J. Gastroenterol. (1985) 20(Suppl. 108):23-35.
35. +-ATPase activity. J. Biol. Chem. (1985) 260:13681-13684.
36. WALLMARK B, LORENTZON P, LARSSON H: The mechanism of action of omeprazole - a survey of its inhibitory action in vivo. Scand. J. Gastroenterol. (1985) 20(Suppl. 108):37-51.
37. +ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). J. Pharmacol. Exp. Ther. (1999) 290:530-534.
38. HORN J: The proton-pump inhibitors: similarities and differences. Clin. Ther. (2000) 22:266-280.
39. +)-ATPase, on bone resorption in humans. Calcif. Tissue Int. (1993) 53:21-25.
40. GRABER ML, DEVINE P: Omeprazole and SCH 28080 inhibit acid secretion by the turtle urinary bladder. Ren. Physiol. Biochem. (1993) 16:257-267.
41. +)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am. J. Physiol. (1994) 266: F868-F877.
42. BISWAS K, BANDYOPADHYAY U, CHATTOPADHYAY I, VARADARAJ A, ALI E, BANERJEE RK: A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J. Biol. Chem. (2003) 278:10993-11001.
43. AGASTYA G, WEST BC, CALLAHAN JM: Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol. Immunotoxicol. (2000) 22:357-372.
44. CIANFRIGLIA M, CENCIARELLI C, TOMBESI M et al.: Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multidrug-resistant variants of CEM cells. Int. J. Cancer (1990) 45:95-103.